Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden flag Sweden · Delayed Price · Currency is SEK
4.880
+0.015 (0.31%)
Feb 21, 2025, 5:24 PM CET

Egetis Therapeutics AB Revenue

Egetis Therapeutics AB had revenue of 9.40M SEK in the quarter ending September 30, 2024, a decrease of -22.95%. This brings the company's revenue in the last twelve months to 67.90M, up 121.17% year-over-year. In the year 2023, Egetis Therapeutics AB had annual revenue of 57.60M with 154.87% growth.

Revenue (ttm)
67.90M
Revenue Growth
+121.17%
P/S Ratio
20.95
Revenue / Employee
1.74M
Employees
28
Market Cap
1.75B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202357.60M35.00M154.87%
Dec 31, 202222.60M-15.60M-40.84%
Dec 31, 202138.20M-2.46M-6.05%
Dec 31, 202040.66M-41.90M-50.75%
Dec 31, 201982.56M54.35M192.66%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Swedish Orphan Biovitrum AB 26.03B
Getinge AB 34.76B
Sectra AB 3.14B
Camurus AB 1.87B
Medicover AB 23.97B
Vitrolife AB 3.61B
Elekta AB 17.88B
BioArctic AB 257.35M
Revenue Rankings